News | Atrial Fibrillation | May 19, 2020

Heart Tissue Changes Can Predict Atrial Fibrillation Prior to Onset

PREDICT-AF trial showed first time there is extensive extracellular matrix remodeling

PREDICT-AF trial showed first time there is extensive extracellular matrix remodeling. #HRS2020 #Heartrhythm2020. Marilyn Fornell

May 19, 2020 — Structural changes of the atrium may occur long before the onset of atrial fibrillation (AF), and the late-breaking PREDICT-AF trial showed first time there is extensive extracellular matrix (ECM) remodeling, which can be used as a new predictor for AF. The study was presented at the Heart Rhythm Society (HRS) 2020 Science virtual meeting.

The Tissue, Blood and Biomarkers to Predict Future Atrial Fibrillation (PREDICT-AF) study showed that extensive ECM remodeling, reaching beyond the deposition of collagens, takes place in the atria of patients long before they develop AF, said Joris R. de Groot, M.D., Ph.D., Amsterdam UMC, Amsterdam, Netherlands, who presented the results. He said the high accuracy of a gene panel to predict future AF may inspire further research to provide targets for diagnosis and primary prevention of AF.

The study included 150 patients (age 68±7 years, 87% men, 115 CABG, 11 valve surgery, 24 combined surgeries). Patients without a history of AF undergoing cardiothoracic surgery with a CHA2DS2-VASc score ≥2 were included and the left atrial appendage was excised (PREDICT-AF NCT03130985). Rhythm monitoring with multiple Holters was performed for 2 years. The primary endpoint was late-onset AF: any atrial tachyarrhythmia >30 sec, occurring >50 days after surgery. The expression of 25 genes related to structural or electrical remodeling was quantified with qPCR in all patients and associated with late-onset AF using Cox-regression analyses. Genes were selected based on a discovery phase (transcriptome sequencing of 22 atrial tissues). Gene panels were used to determine C-statistics.[1] 

Median follow-up was two years [1.5-2]. Post-operative AF occurred in 63 (42%) patients ≤50 days post-surgery and late-onset AF in 18 (12%). Gene expression of all 25 genes was similar in patients with and without post-operative AF <50 days. Patients with late-onset AF exhibited numerical down regulation of KCNJ2 and up regulation of SCN2B. There was a marked increased expression of extracellular matrix (ECM) genes encoding collagens and matricellular proteins that act as structural proteins and fibrogenic mediators. We found a strong correlation between ECM genes and the fibroblast activator Endothelin-1. 

The fraction of Vimentin positive cells (i.e. fibroblasts) was similar, suggesting fibroblast activation rather than proliferation. A gene panel including KCNJ2, COL8A2, and COL1A1 better discriminated late-onset AF (AUC=0.82) than a model with the most relevant clinical parameters (age≥75, LAVI and sex; AUC=0.69).

Find links to all the Heart Rhythm Society 2020 Late-Breaking Clinical Trials in Electrophysiology

Reference:

1. PREventive Left Atrial appenDage Resection for the predICtion of fuTure Atrial Fibrillation: Design of the PREDICT AF Study. J Cardiovasc Med (Hagerstown). 2019 Nov;20(11):752-761. doi: 10.2459/JCM.0000000000000868.

 

Related Content

The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evaluated the detection of silent, or previously undiagnosed, atrial fibrillation (AF) in moderate-risk individuals using the FDA-cleared Zio by iRhythm ambulatory monitoring patch. The results support the clinical value of early screening and targeted detection in moderate-risk populations. #AHA #AHA20 #AHA2020

The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evaluated the detection of silent, or previously undiagnosed, atrial fibrillation (AF) in moderate-risk individuals using the FDA-cleared Zio by iRhythm ambulatory monitoring patch. The results support the clinical value of early screening and targeted detection in moderate-risk populations.

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 — The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evalu
The Medtronic SEEQ mobile cardiac telemetry system, pictured here, and the Icentia CardioSTAT cardiac rhythm monitoring device both found in reased rates of post-operative atrial fibrillation in the SEARCH-AF trial presented at the American Heart Association annual meeting. #AHA #AHA20 #AHA2020

The Medtronic SEEQ mobile cardiac telemetry system, pictured here, and the Icentia CardioSTAT cardiac rhythm monitoring device both found in reased rates of post-operative atrial fibrillation in the SEARCH-AF trial presented at the American Heart Association annual meeting.

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 — Atrial fibrill...
The Medtronic Arctic Front cryoballoon balloon was used a a front-line treatment of AF in the EARLY-AF trial. It was found to be better than anti-arrhythmic drugs in preventing the recurrence of abnormal heart rhythm (atrial tachyarrhythmia, atrial fibrillation), and improve patient well-being.  #AHA #AHA2020 #AHA20

The Medtronic Arctic Front cryoballoon balloon was used a a front-line treatment of AF in the EARLY-AF trial. It was found to be better than anti-arrhythmic drugs in preventing the recurrence of abnormal heart rhythm (atrial tachyarrhythmia, atrial fibrillation), and improve patient well-being.  

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 – Doctors from the Mo...

The study used cadaver hearts that were images with contrast enhanced MRI and the images used to create a 3-D computation model of the electrical activation in the heart and how it was influenced by adenosine and ablation. Find more images in the original article

News | Atrial Fibrillation | October 08, 2020
October 8, 2020 – People who suffer from persistent atrial fibrillation in the heart may find relief from a new treat
The TactiFlex PAF investigational device exemption (IDE) study will evaluate he investigational TactiFlex Ablation Catheter, Sensor Enabled (SE) to treat people suffering from paroxysmal atrial fibrillation (PAF). 

The TactiFlex PAF investigational device exemption (IDE) study will evaluate he investigational TactiFlex Ablation Catheter, Sensor Enabled (SE) to treat people suffering from paroxysmal atrial fibrillation (PAF). 

News | Atrial Fibrillation | August 04, 2020
August 4, 2020 — Abbott announced the first enrollments in the TactiFlex PAF  investigational device exemption (IDE)
Results of the Atrial Fibrosis Predicts Recurrent Stroke Or New Atrial Fibrillation In Patients With Embolic Stroke Of Undetermined Source - A Multi-Center Study at HRS 2020. #HRS2020 #Heartrhythm2020,
News | Atrial Fibrillation | May 19, 2020
May 19, 2020 — Atrial disease has been implicated in embolic stroke of undetermined source (ESUS) and a late-breaking
Contact Force Sensing Catheter Improved Outcomes in Persistent Atrial Fibrillation Ablation. #HRS2020 #heartrhythm2020
News | Atrial Fibrillation | May 13, 2020
May 13, 2020 — The PRECEPT study testing the use of the Biosense Webster Thermocool Smarttouch SF Catheter for the tr